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at www.jvascsurg.org.DISCUSSIONDr Frank LoGerfo (Boston, Mass). What comes ﬁrst? Do the
macrophages somehow change the phenotype of the smooth
muscle cells? I guess that’s the ﬁrst thing that comes to mind in
an inﬂammatory process. If so, then why do the macrophages
do that? What is the stimulus? Are there some receptors at theendothelial level? What causes the macrophages to get involved
here?
Of course, this could all be wrong. There could be a primary
phenotypic difference in the smooth muscle cells in the aortic wall
right from the start. But, it would seem more likely that the
JOURNAL OF VASCULAR SURGERY
1042 Airhart et al October 2014phenotypic change comes after this inﬂammatory process. I’d
appreciate your thoughts about that.
Dr Nathan Airhart. Our hypotheses is that it may be the
smooth muscle cell that’s coming ﬁrst. As I discussed, the smooth
muscle cells that we are culturing from abdominal aortic aneurysms
are unique. They exhibit a unique phenotype in culture which
favors the degradation of elastin and this is a phenotype that
persists, even through several passages in cell culture. One poten-
tial explanation for this phenomenon may be that the smooth
muscle cells that populate the region of the infrarenal aorta have
a distinct embryologic origin. Interestingly, the embryologic
boundaries of these cells happen to match up with where more
than 90% of abdominal aortic aneurysms occur.
The nature of this study, and virtually all studies using patho-
logic specimens from human abdominal aortic aneurysm disease,
prevents us from answering the speciﬁc question, “which comes
ﬁrst, the inﬂammation or the smooth muscle cell,” as our cell
cultures are coming from very late-stage abdominal aortic aneu-
rysm tissue. However, the way that these cells from the infrarenal
aorta react to chronic stresses (abdominal aortic aneurysm risk
factors), such as smoking, atherosclerosis, or hemodynamic pres-
sure, may be different than smooth muscle cells from different
regions of the aorta or from those cells from individuals who do
not develop aneurysms.
Dr Alexander Clowes (Seattle, Wash). One of the obser-
vations made in the past is that the medial smooth muscle cells
die as aneurysms form. In our own studies of vascularadaptation, we have found that as smooth muscle cells undergo
apoptosis, they produce a lot of proteolytic activity and
degrade the surrounding matrix. It is very remarkable. I would
like to know whether the macrophages in your experiments are
killing the smooth muscle cells and whether the dying smooth
muscle cells are, in turn, secreting elastolytic and proteolytic
activity.
Dr Airhart. Currently, we do not have evidence that co-
culture with macrophages is inducing cell death in our smooth
muscle cells. We have not done objective studies to answer this
question, however, and it is something that we should look at
more closely.
Dr B. Timothy Baxter (Omaha, Neb). I have two questions
for you. Can you tell us about growing these cells out? Usually the
smooth muscle cells are much more difﬁcult to grow, and they
grow slower. And, so really you have two different populations.
And, I wonder if there is some selection in that process?
The second thing is activation of MMP-2. Did you happen to
look at MMP-14/MT1-MMP which is the activator of MMP-2?
Dr Airhart.We chose to focus on matrix metalloproteinase-2
and matrix metalloproteinase-9 after seeing the results from our
microarray data. We haven’t done any further validation with the
other MMPs.
We have had excellent success culturing smooth muscle cells
from the pathologic tissue. I think that this really comes from exten-
sive experience with the culture technique, careful attention to
tissue dissection, and maintenance of optimal culture conditions.
